The 2018 Global Market for Contract Research Organization (CRO) Services (2016-2022)

Dublin, Dec. 11, 2018 (GLOBE NEWSWIRE) -- The "Global Market for Contract Research Organization (CRO) Services" report has been added to ResearchAndMarkets.com's offering.

Analyses of global market trends, with data from 2016, 2017, and projections of compound annual growth rates (CAGRs) through 2022

The Global CRO market is identified in this report along with all major global CRO companies.

The total CRO market is broken out globally and by geographic region. Additionally, all major therapeutic areas covered by CROs in the clinical trial process are detailed. The service areas provided by CROs are extensively covered as well. The phases of the clinical trial process and the role provided by CROs are detailed in this report as well.

This report provides a detailed analysis of top CRO companies and their evolving role in the clinical trial process. Faced with rapid development of new therapies, Pharmaceutical companies are increasingly turning to CROs for their services. CRO's expertise within specific therapeutic areas as well as their experience with new and adaptive study design protocols can reduce costs and study duration.

With typical clinical trials costing upwards of $2.5 billion and spanning over a decade from initial testing to Phase IV and post-market approval, a thriving market exists to lower these costs and timelines. CROs are expected to continue to play an increasing role in many facets of the clinical trial process.

Oncology, neurology, cardiovascular, metabolism-diabetes, vaccines and other rapidly growing therapeutic areas that have a significant number of drugs in the clinical trial process are detailed in this report.

Strong demand for CRO services is leading to heightened market valuations and correspondingly a plethora of blockbuster Merger and Acquisition deals are taking place. M&A activity has led to a few powerful companies with expertise across many areas of the clinical trial process, although many niche players are still playing a critical role. These emerging trends and changing dynamics within the CRO industry are analyzed in detail in this report.

Executive Summary

All segments, including preclinical and post-approval, continue to grow solidly as well. The outlook for the industry remains extremely positive; with the proliferation of therapies for orphan drugs and precision-based medicines, clinical trials are becoming increasingly complex and are driving demand for sophisticated outsourcing partners with expertise in combination products, risk-based monitoring, disease registries, real-world evidence, and medical affairs. Expanding service offerings and capabilities remain a predominant strategy among CROs.

CROs obtain the lion's share of their revenue from actual clinical trials. Discovery, preclinical and central lab services all represent strong areas of growth despite accounting for a smaller share of revenue.

The geographical distribution of clinical trials is slowly shifting from developed nations to emerging countries; rising costs of trials and difficulty in patient recruitment has led biopharma companies to shift toward regions such as Central and Eastern Europe, Asia-Pacific and Latin America for quicker patient recruitment and cost savings. The greater disease variation among developing countries also helps create more diverse population samples, particularly for rare disease studies.

Based on the indication, the oncology segment is the largest and one of the most rapidly growing within the CRO space. Pain management remains one of the faster growing and more lucrative disease areas, with new treatments for chronic and acute pain and rising investigational studies for Non-Steroidal Anti-Inflammatory Drug (NSAID) and analgesic molecules driving this segment.

The dominant players in the industry are Quintiles IMS, Covance, PAREXEL, Charles River Labs and ICON. Mergers and acquisitions by these and other larger companies in this space continue at an unprecedented pace; high valuations along with the increasing need to become complete service providers are driving this trend.

Key drivers impacting CRO market growth include globalization of clinical trials, development of new treatments such as personalized medicine, augmenting evolution of technology and greater penetration of CROs into the clinical trial process. The demand or biogenetics and particularly biosimilars will be a clear driver going forward.

Current pharma R&D spending is being driven by precision-based medicines and immunotherapies for smaller populations, genetic therapies for oncology and rare disease treatment and generally more demanding and complex protocols for drug development.

The clinical trial environment continues to be tied to exorbitant costs as complex therapies requiring larger and more diverse samples are extending the time required and geographies involved to conduct a typical study. In an effort to contain these costs and shorten development timelines, pharma and biopharma firms are increasingly outsourcing many services associated with the development of today's complex therapies to CROs.

Key Topics Covered

Chapter 1 Introduction

• Global CRO Market Trends
• Study Goals and Objectives
• Reasons for Doing This Study
• Scope of Report
• Information Sources
• Methodology
• Geographic Breakdown
• Analyst's Credentials
• Custom Research
• Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Overview-Clinical Trial Process and CRO Functional Services

• Clinical Trial Process and Stages
• Pre-discovery
• Drug Discovery
• Preclinical
• Clinical
• Phase I
• Phase II
• Phase III
• Post-Marketing Surveillance and Phase IV Studies
• Regulatory Environment
• FDA Regulation and Impact
• The Declaration of Helsinki
• CDISC Standards
• Current Market Trends
• Repurposing Existing Drugs for New Indications
• Increased Competition through the Resurgence of the Generic Drug Market

Chapter 4 Global Market Overview

• Global Clinical Trials Shifting toward Asia-Pacific

Chapter 5 Emerging Trends

• Increasing Complexity of Clinical Trials
• Small and Mid-sized Biopharma Innovation
• Small Molecule Versus Biologics
• Biosimilars
• Adaptive Trial Design
• Risk-Based Monitoring
• Real World Evidence

Chapter 6 Competitive Landscape

• Functional Service Provider Relationships
• Offshoring
• Therapeutic Areas in Drug Development
• Immuno-Oncology
• Current Pharma-CRO Contracts
• Largest Therapeutic Areas Rely on Key CRO Expertise

Chapter 7 Mergers and Acquisitions

• Recent Merger and Acquisition Activity
• Quintiles IMS
• LabCorp, Covance, and Chiltern
• INC Research/Inventiv Health
• ICON and MAPI
• Parexel and Pamplona

Chapter 8 Company Profiles

• Top 10 CROs
• Charles River Laboratories
• Concord Biosciences
• Icon Plc
• INC Research/Inventive Health
• LabCorp/Covance
• Parexel
• Pharmaceutical Product Development
• PRA Health Services
• Quintiles
• Wuxi Apptec

For more information about this report visit https://www.researchandmarkets.com/research/nn6g5g/the_2018_global?w=12

                    CONTACT: ResearchAndMarkets.com
                             Laura Wood, Senior Press Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                    Related Topics: Biotechnology, Drug Discovery